Gain Therapeutics, Inc. (GANX) |
|
4.62 -0.055 (-1.18%)
|
03-17 16:00 |
|
Open: |
4.8 |
Pre. Close: |
4.675 |
|
High:
|
4.95 |
Low:
|
4.62 |
|
Volume:
|
99,547 |
Market Cap:
|
55(M) |
|
|
|
Technical analysis |
as of: 2023-03-17 4:19:28 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 5.78  One year: 6.75 |
| Support: |
Support1: 4.1 Support2: 3.58 |
| Resistance: |
Resistance1: 4.94 Resistance2: 5.78 |
| Pivot: |
4.07 |
| Moving Average: |
MA(5): 4.41 MA(20): 4.09
MA(100): 3.54 MA(250): 3.56 |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 85.5  %D(3): 84.4 |
| RSI: |
RSI(14): 64.3 |
| 52-week: |
High: 6.69 Low: 2.32 |
| Average Vol(K): |
3-Month: 54 (K) 10-Days: 108 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GANX ] has closed below upper band by 6.7%. Bollinger Bands are 118.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.8 - 4.82 |
4.82 - 4.83 |
|
Low:
|
4.3 - 4.32 |
4.32 - 4.33 |
|
Close:
|
4.64 - 4.67 |
4.67 - 4.7 |
|
Company Description |
|
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland. |
Headline News |
Fri, 17 Mar 2023
Is Gain Therapeutics Inc (GANX) Stock About to Get Hot Friday? - InvestorsObserver
Wed, 15 Mar 2023
Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue ... - Nasdaq
Mon, 13 Mar 2023
Is Gain Therapeutics Inc (GANX) Stock a Bad Value Monday? - InvestorsObserver
Thu, 09 Mar 2023
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual ... - The Bakersfield Californian
Tue, 07 Mar 2023
Should Biotechnology Stock Gain Therapeutics Inc (GANX) Be in Your Portfolio Tuesday? - InvestorsObserver
Mon, 27 Feb 2023
Gain Therapeutics Presents New Preclinical Data from its Gaucher ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
12 (M) |
|
% Held by Insiders
|
9.18e+006 (%) |
|
% Held by Institutions
|
24.3 (%) |
|
Shares Short
|
19 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.64e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-9 |
|
Return on Assets (ttm)
|
719.7 |
|
Return on Equity (ttm)
|
-29 |
|
Qtrly Rev. Growth
|
168980 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.03 |
|
Qtrly Earnings Growth
|
-1.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-15 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
562.41 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
22400 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
